Tafinlar Set For Indian Approval?
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline's melanoma therapy, Tafinlar (dabrafenib mesylate), appears to have inched closer to an approval in India after a key expert panel exempted it from local trial requirements. However, the product will form part of Novartis's portfolio following the two firms’ global asset swap transaction last year.